Nguyen Patrick Viet-Quoc, Boidin Constance, Bouin Mickael
J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1197-1202. doi: 10.1016/j.japh.2023.05.006. Epub 2023 May 8.
Health care deciders are aware of the inappropriate use of proton pump inhibitors (PPIs). To reduce inappropriate prescriptions, the Conseil du Médicament (CdM) issued a practice guideline and the Régie de l'Assurance Maladie du Quebec (RAMQ) asked prescribers to justify its use by writing a specific indication code for their patients to obtain drug coverage.
This study aimed to evaluate the effectiveness of the intervention by the RAMQ to reduce inappropriate PPI prescription.
A cross-sectional quasi-experimental prospective study was performed in an emergency department. Patients aged 18 years or older were included in 2016 to 2017 and 2019 to 2021 in the pre- and postintervention group, respectively. The proportion of patients on PPI without an appropriate indication were identified from patient interviews and chart review.
A total of 871 and 1475 patients were recruited in the pre- and postintervention groups. According to the CdM guideline, the proportion of inappropriate PPI prescription was 30.7% (n = 267) in the preintervention group and 49.1% (n = 724) in the postintervention group (P < 0.001). According to the RAMQ criteria, the proportion of inappropriate PPI prescription was of 76.1% (n = 663) and 81.4% (n = 1200) in the pre- and postintervention group, respectively (P < 0.001).
This study highlights the ineffectiveness of the codes for PPI prescriptions in reducing inappropriate prescriptions. It seems that the obligation to write a code does not lead to a reassessment of PPI indication.
医疗保健决策者意识到质子泵抑制剂(PPI)存在使用不当的情况。为减少不适当的处方,药品委员会(CdM)发布了一项实践指南,魁北克医疗保险局(RAMQ)要求开处方者通过为患者书写特定的适应症代码以获得药物保险来证明其使用的合理性。
本研究旨在评估RAMQ的干预措施在减少不适当PPI处方方面的有效性。
在一家急诊科进行了一项横断面准实验性前瞻性研究。分别于2016年至2017年及2019年至2021年将18岁及以上的患者纳入干预前组和干预后组。通过患者访谈和病历审查确定无适当适应症而使用PPI的患者比例。
干预前组和干预后组分别招募了871名和1475名患者。根据CdM指南,干预前组不适当PPI处方的比例为30.7%(n = 267),干预后组为49.1%(n = 724)(P < 0.001)。根据RAMQ标准,干预前组和干预后组不适当PPI处方的比例分别为76.1%(n = 663)和81.4%(n = 1200)(P < 0.001)。
本研究强调了PPI处方代码在减少不适当处方方面的无效性。看来书写代码的义务并未导致对PPI适应症的重新评估。